The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis

[1]  D. Gomez,et al.  Tumor invasion, proteolysis, and angiogenesis , 2005, Journal of Neuro-Oncology.

[2]  S. Yamamoto,et al.  Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis , 2004, Cancer Research.

[3]  N. Brünner,et al.  Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies , 1995, Breast Cancer Research and Treatment.

[4]  K. Kilpatrick,et al.  Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist , 2004, Clinical & Experimental Metastasis.

[5]  R. Khokha,et al.  Molecular mechanisms of tumor invasion and metastasis: an integrated view. , 2003, Current molecular medicine.

[6]  P. Wen,et al.  Neurologic Complications of Cancer , 2003 .

[7]  R. Gerard,et al.  Both u‐PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis , 2002, International journal of cancer.

[8]  G. Kéri,et al.  A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. , 2002, In vivo.

[9]  D. Sheppard,et al.  Plasmin-Sensitive Dibasic Sequences in the Third Fibronectin-like Domain of L1–Cell Adhesion Molecule (CAM) Facilitate Homomultimerization and Concomitant Integrin Recruitment , 2000, The Journal of cell biology.

[10]  M. Duffy,et al.  Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin , 2000, International journal of cancer.

[11]  S. Carsons,et al.  Fibronectin fragments and their role in inflammatory arthritis. , 2000, Seminars in arthritis and rheumatism.

[12]  A. Young,et al.  Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  R. Gerard,et al.  Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors , 1999, Gene Therapy.

[14]  L. Illis.  Harrison's Principles of Internal Medicine 14th Edition , 1998, Spinal Cord.

[15]  B. Nielsen,et al.  Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice , 1998, Oncogene.

[16]  S. Strickland,et al.  Neuronal Death in the Hippocampus Is Promoted by Plasmin-Catalyzed Degradation of Laminin , 1997, Cell.

[17]  Y. Wei,et al.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. , 1997, The Journal of clinical investigation.

[18]  F. Gilles,et al.  Selective expression of adhesion molecules on human brain microvascular endothelial cells , 1997, Journal of Neuroimmunology.

[19]  N. Prasadarao,et al.  Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: Development of an immortalized cell line to study pathophysiology of CNS disease , 1997, In Vitro Cellular & Developmental Biology - Animal.

[20]  M. Weinand,et al.  A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. , 1997, Journal of immunology.

[21]  B. M. Mueller,et al.  Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system , 1997, International journal of cancer.

[22]  C. Rüegg,et al.  Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. , 1997, Journal of immunology.

[23]  P. Richardson,et al.  Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Rabbani,et al.  Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis , 1996, International journal of cancer.

[25]  E. Arbit,et al.  Clinical decision making in brain metastases. , 1996, Neurosurgery clinics of North America.

[26]  R. Sawaya,et al.  Neurologic Complications of Cancer. , 1996 .

[27]  M. Duffy,et al.  Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. , 1996, Enzyme & protein.

[28]  A. Mazar,et al.  Prevention of prostate‐cancer metastasis in vivo by a novel synthetic inhibitor of urokinase‐type plasminogen activator (uPA) , 1995, International journal of cancer.

[29]  Roy A. Patcheil.  Metastatic brain tumors. , 1995 .

[30]  P. Carmeliet,et al.  Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. , 1995, Circulation.

[31]  J. Hoover-Plow,et al.  The cell biology of the plasminogen system , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  L. Steinman,et al.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. , 1994, The Journal of clinical investigation.

[33]  Stetler-Stevenson Wg.  Progelatinase A activation during tumor cell invasion. , 1994 .

[34]  W. Stetler-Stevenson.  Progelatinase A activation during tumor cell invasion. , 1994, Invasion & metastasis.

[35]  F. Jänicke,et al.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. , 1992, Biological chemistry Hoppe-Seyler.

[36]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[37]  C. Bucana,et al.  Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice , 1989, International journal of cancer.

[38]  I. Fidler,et al.  Development of in vivo models for studies of brain metastasis , 1988, International journal of cancer.

[39]  J. Tew,et al.  Antifibrinolytic therapy of experimentally grown malignant brain tumors. , 1986, Journal of neurosurgery.

[40]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[41]  T. Fujii,et al.  Metastatic Brain Tumors , 1981 .

[42]  K Takakura,et al.  [Metastatic brain tumors]. , 1980, Rinsho hoshasen. Clinical radiography.

[43]  W. B. Butler,et al.  Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). , 1979, Biochemical and biophysical research communications.

[44]  J. Posner,et al.  Intracranial metastases from systemic cancer. , 1978, Advances in neurology.

[45]  D Riddoch,et al.  Neoplasms of the central nervous system. , 1977, The Practitioner.

[46]  L. Elveback,et al.  Neoplasms of the central nervous system , 1972, Neurology.

[47]  Francis J. Castellino,et al.  The Mechanism of the Inhibition of Plasmin Activity by ε-Aminocaproic Acid , 1971 .

[48]  D. Gitlin,et al.  DEOXYRIBONUCLEIC ACID METABOLISM IN VIVO: I. CELL PROLIFERATION AND DEATH AS MEASURED BY INCORPORATION AND ELIMINATION OF IODODEOXYURIDINE. , 1964, Federation proceedings.